Roivant Sciences Ltd

• Country

  United Kingdom

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  8815.9

• Ticker

  ROIV.O

• ISIN

  BMG762791017

• IPO date

  2020-12-03

• Availability on Russian exchanges

  No

• Reporting for

  2024-02-13

• Date fact. publication of reports

  2023-12-31

Roivant Sciences Ltd. is a biopharmaceutical company. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploy technology to drive research and development and commercialization. Its drug discovery capabilities include a computational physics-based platform for in silico drug design and machine learning-based models for protein degradation. Its development-stage product candidate includes Tapinarof, Cerdulatinib, IMVT-1401, ARU-1801, Namilumab, LSVT-1701, Cerdulatinib, DMVT-504, DMVT-503, ARU-2801, AFM32 and CVT-TCR-01. Its Vant family include Dermavant, Immunovant, Aruvant, Proteovant, Lysovant, Kinevant, Affivant, Cytovant, Arbutus, Sio Gene Therapies, Genevant, Silicon Therapeutics, VantAI, Lokavant, Datavant and Alyvant.